A Systematic Review of Patient Reported Outcomes Associated with the Use of Direct-
acting Oral Anticoagulants

Saima Kishvar Afzal¹*, Syed Shahzad Hasan¹, Zaheer Ud-Din Babar¹

¹University of Huddersfield, Queensgate, HD1 3DH, Huddersfield, West Yorkshire, United Kingdom

*Principal investigator

Keywords Direct-acting oral anticoagulants, patient reported outcomes, systematic review, warfarin

Correspondence
Saima Kishvar Afzal
University of Huddersfield, Queensgate, HD1 3DH, Huddersfield, West Yorkshire, United Kingdom
Email: s.afzal@hud.ac.uk
Telephone: 01484 471785
Abstract

AIMS: Patient reported outcomes (PROs) are a distinctive method of evaluating patient’s response to health care or treatment. This study aimed to analyse the impact of PROs in patients on DOAC treatment, prescribed for any indication (e.g. VTE treatment or AF) using controlled trials (CT) and real world observational studies (OS).

METHODS: A systematic search of articles was conducted according to PRISMA guidelines using databases, with the last update in November 2018. The Cochrane Collaboration tool for assessing bias in RCTs and the Newcastle-Ottawa Scale adapted for cross-sectional studies were used. Outcomes evaluated were related to Health Related Quality of Life (HRQoL), satisfaction, adherence and compliance.

RESULTS: Twenty-one original studies (CT=6 & OS=15) were included. HRQoL was assessed by 6 (CT=1 & OS=5) studies and reported that HRQoL scores were similar in patients on DOACS and warfarin. Patients prescribed DOACs presented higher HRQoL scores which were attributed to lack of intense monitoring required compared with warfarin but this was not statistically significant. The majority of studies (CT=5 & OS=9) investigated patient reported satisfaction indicating greater satisfaction with DOACs with significantly lower burden and increased benefit scores for patient on DOACs. Patient reported expectations, compliance and adherence were similar for patients on DOACS and warfarin.

CONCLUSION: Patients appear to prefer treatment with DOACS versus warfarin. This has been exhibited by the higher QoL, satisfaction and adherence described in the studies. However, heterogeneity in the analysed studies does not allow firm conclusions.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

Direct Oral Anticoagulants have revolutionised treatment of VTE and prevention of stroke due to AF with demonstrated similar efficacy and safety as warfarin. PROS are an optimum method of evaluating patients’ perceptions of these agents.

WHAT THIS STUDY ADDS

Patients report higher satisfaction, adherence and enhanced quality of life with DOACs compared to warfarin therefore indicating a higher preference for these agents.

Introduction

Inception of new (or direct) oral anticoagulants (NOACs or DOACs) have brought a new dawn to the treatment of thromboembolic conditions such as non-valvular atrial fibrillation and treatment or prophylaxis of venous thromboembolism (deep vein thrombosis, (DVT) and pulmonary embolism, PE). These direct oral anticoagulants (e.g. apixaban, rivaroxaban, dabigatran and edoxaban) have made rapid progress in revolutionising anticoagulation and been extensively investigated and researched in clinical trials for their clinical effectiveness and safety profile in comparison with standard treatment 1.

Anticoagulation with warfarin, a potent vitamin K antagonist, has been the mainstay of treatment for prophylaxis, treatment and long-term management of thromboembolic conditions such as venous thromboembolism (VTE) atrial fibrillation (AF) and stroke. Use of warfarin effectively is associated with a significant reduction in the risk of stroke and mortality associated with AF 1. However, warfarin use is limited by its narrow therapeutic index requiring regular monitoring of INR, multiple drug interactions and dietary restrictions 2. Over the past decade, the introduction of DOACs, have revolutionised the treatment of these conditions without the complications associated with warfarin. DOACs have also been recognised as a safe and effective treatment option in thromboprophylaxis post orthopaedic surgery. However, these agents have been known to carry a potential risk of bleeding with no actual method of anticoagulation reversal 3,4.
DOACs have been accredited with reducing complications which arise through monitoring and individual-dosing of VKAs. Dabigatran was first approved for use within the UK for AF and VTE in 2011 following results of the RELY trial. Rivaroxaban approval followed showing non-inferiority to warfarin for the prevention of AF and VTE in the ROCKET AF study in 2011. The ARISTOTLE trial led to the licensing of apixaban in 2012 showing that apixaban was superior to warfarin in preventing stroke in AF patients and VTE. Edoxaban was approved in 2015 after the result of the ENGAGE-AF trial displaying non-inferiority of edoxaban to warfarin. These clinical studies emphasised the clinical efficacy of the DOACs versus warfarin with the enhanced benefit of a reduced intracranial and major bleeding however showed a higher risk of GI bleeding. Nevertheless, the European society of Cardiology and NICE have recommended DOACs as a suitable option for non-valvular AF over warfarin.

Patient-reported outcomes (PROs) are testimonies from the patient about how they feel about any particular condition or treatment they are receiving without any intervention or bias from the clinicians. PROs include any evaluation of treatment or outcome directly from patient interviews, questionnaires or specifically developed tools to capture and enable analysis of valuable patient-reported data. PROs provide valuable data from the patient’s perspective and are sometimes used as primary outcomes from clinical trials. However, more often PROs are conveyed as sub-analyses after the initial trials have been published.

PROs are subjective measures relating to patient experience and quantify assessment of patient satisfaction, adherence or health related quality of life (HRQoL). HRQoL can be defined as an evaluation of impairment, disability or handicap. Patient satisfaction determines perceived burden or benefits of the perceived treatment being appraised.

The Anti-clot Treatment Score (ACTS), Treatment Satisfaction Questionnaire for Medication (TSQM) and Perception of Anticoagulation Questionnaire (PACT) are tools used to assess satisfaction. The Duke Anticoagulation Satisfaction Scale has been specifically developed to measure both satisfaction and HRQoL. Patient reported adherence can be evaluated using self-report scales such as the Morisky 4 or 8-item adherence scale. These tools measure disease or treatment-specific objectives describing severity of symptoms, benefit, adverse drug effects in order to capture the patients’ well-being and experience with the intervention. Such tools have been developed to measure PROs in patients receiving anticoagulation and have been scrutinised and validated prior to use.
A recent systematic review by Generalova et al explored clinicians’ views and experiences of DOACs in patients with AF presenting evidence of clinician preference in recommending DOACS as first choice for these patients. However, publishing/reporting of PROs from clinical trials have been limited and to date there are no systematic reviews conducted which evaluate or cumulatively analyse the results of PROs in patients prescribed DOACs. This systematic review aims to bridge this gap in knowledge and enhance understanding of PROs in anticoagulation with DOACs. The aim of the current review is to systematically assess the PROs reported by adults receiving DOACs, with additional focus on patient satisfaction, adherence, compliance and health-related quality of life (HRQoL) using original studies (controlled trials and observational real-world studies).
Methods

Scope of review: eligibility criteria
The systematic review process was conducted following PRISMA guidelines. The primary investigator (SKA) applied the eligibility criteria to examine abstracts of original journal articles published in English that (a) Patient Reported Outcomes (PROs) and (b) new or direct oral anticoagulants (DOACs) namely apixaban, rivaroxaban, dabigatran or edoxaban were included. Finally, abstracts had to report PROs based on a recognized PRO tool with measurable outcomes. The following types of studies were excluded: review articles, observational studies and articles on compliance or persistence which focussed on tablet count or prescription monitoring.

For population attributes, studies that were included that assessed PROs in adults being treated with a DOAC. The search was restricted to: studies involving humans and original journal articles. Titles and abstracts were screened to remove studies that were irrelevant to the aim of the review and full texts of the remaining studies that analysed the required data but did not utilise a recognised PRO tool were excluded.

Information sources
The following databases were searched between September 2018 and October 2018 with no filters set on publication date: PubMed (United States National Library of Medicine), Cumulative index to Nursing and Allied Health Literature (CINAHL – Elsevier, Amsterdam, Netherlands), MEDLINE (Medical Literature Analysis and Retrieval System Online, or MEDLARS Online), Embase (Excerpta Medica database) from 1974 until September 2018, SCOPUS and Springer Link databases. Google scholar was also searched to identify articles not indexed in scientific databases. References cited in the reference list of each identified original research were scanned for any additional articles that would be relevant to this review; these were subsequently also scanned for reviews and studies which may have been relevant and which were subject to the same eligibility evaluation.

Searching
The search strategy identified original research on patient-reported outcomes associated with the use of new or direct oral anticoagulants. Search terms were constructed using a
Population (P), Intervention (I), Outcome (O) model and considered the following strategy limited to “adults (limit: 18+ years), humans and English language”. Search terms were Anticoagulant* OR oral anticoagulant* OR novel oral anticoagulant* OR Non Vitamin K antagonist oral anticoagulant* (NOAC) OR vitamin K antagonist oral anticoagulant* OR coumarin* OR dabigatran OR rivaroxaban OR apixaban OR edoxaban OR warfarin OR direct factor Xa inhibitor* OR direct thrombin inhibitor* AND Patient reported outcomes OR patient reported satisfaction OR patient reported adherence OR quality of life.

Study selection
After possible studies were identified, all retrieved titles were screened by the primary investigator (SKA) to determine their potential relevance. The assessed abstracts were independently by another investigator (SSH) against five inclusion criteria: (i) original research studies; (ii) recognised and validated tool to measure PROs; (iii) patients were taking a DOAC for >4 weeks; (iv) adult subjects (≥19 years of age); and (v) reported in English. Full papers from potential studies were independently assessed by the investigators (SKA and SSH).

Data collection process
All studies selected for this systematic review were screened by two reviewers independently to validate the results. The purpose, study design, number of participants, description of observations, and outcome measures were recorded. The data from all the retrieved studies were subsequently collected and tabulated using a form developed by the lead author that was verified by the second reviewer. Extracted information from studies is mentioned in Table 1. The extracted information included study design, study participants and settings, objectives of the study, response rate and sample size, outcomes measured, summarized results and main findings of the study.

Classification of Outcomes
The outcome measures were categorized into 3 main groups, namely health related quality of life (HRQoL), patient reported satisfaction and patient reported adherence/compliance or expectations related to anticoagulation treatment with DOACs.
Assessment of quality and risk of bias in included studies

The lead author independently assessed the risk of bias of each of the included studies and discussed their assessments with other two authors to achieve consensus. The six-item risk of bias assessment was used as it is a validated method of analysing bias within randomised controlled trials. The criteria for judging include random sequence generation of the study sample, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other issues which may indicate bias. The modified Newcastle-Ottawa Scale was selected because it was easier to use and considered reliable to measure biasness in cross-sectional studies. Each of the selected cross-sectional studies was evaluated for selection, comparability and outcome bias. The lead author rated each paper using the NOS assessment methods for selecting study participants, methods to control confounding, using appropriate statistical methods and methods for measuring outcome variables.
**Results**

**Search Results and Study Characteristics**

The search yielded 3285 unique titles (1964 from PubMed, CINAHL, Medline and EMBASE with an additional 1321 titles from SCOPUS, Springer Link and Google Scholar). After removal of duplicate records, 3231 abstracts were screened. Of these, 3,104 studies were excluded. Of the remaining 127 articles, 97 were excluded as they did not describe original research or did not illustrate patient reported outcomes or focussed on warfarin alone. The search yielded 11 articles which were excluded because they involved investigations on adherence or persistence based on pill taking patterns, tablet counting or prescription fill analysis rather than patient reported outcomes. A total of 21 studies were ultimately included in the review, 6 controlled trials and 15 observational studies (Figure 1). The 21 studies evaluated patient reported outcomes or quality of life, using a validated tool, associated with the use of DOACs. The controlled trials (n = 6) included 5 randomized and 1 non-randomized trial (see Table 1). Controlled trials were used as they provide larger scale trials within controlled environments however due to being sponsored by industry often may contain an element of bias and not present the full patient overview. Real-world observational and cross sectional studies provide actual patient experience and use of the treatment in practice. Of the 6 controlled trials, 5 were conducted in multiple countries (including UK, US, Canada, Netherlands, France, Germany and Italy) and one was conducted in Japan. The observational studies (n = 15) used the following study designs: 11 prospective studies conducted in Spain, France, Canada, Japan, US, Australia and Europe. Four of the studies were cross-sectional studies conducted in Spain, France and Canada (see Table 1).

**Risk of Bias Within Studies**

In the case of controlled trials, 5 studies used randomized methods to generate the sequence and 1 study used some form of data checking for patient selection (see Table 2). However, only 3 studies clearly described a form of concealed allocation and personnel and participant blinding. Hence, none of the studies satisfied all 6 key criteria together. In respect to the observational studies, the NOC scale was used for quality assessment (see Table 3). Of the 15 observational studies, 6 were good studies with a score of 7-8 points. Eight of the studies were regarded as satisfactory studies with a score of 5-6 points. Only
one study was considered as an unsatisfactory study with a score of only 4 points due its absence of the use of a validated PRO tool \(^4\). Quality issues often lacking were blinding of the outcome assessment, identification of potential confounders, assessment of the subjects’ likelihood of the outcome upon enrolment, and validity and reliability of the outcome assessment tools.

**Study Outcomes**

HRQoL was reported in five studies and used the Euro-QoL utility and visual analog scores which covered 5 dimensions (consisting of mobility, autonomy, usual activities, pain/discomfort, anxiety/depression) or the Sawicki questionnaire (which is a 32 items questionnaire grouped covering general treatment satisfaction, self-efficacy, strained social network, daily hassles and distress) \(^14,45,46\). The majority of the studies (14 studies) described patient reported treatment satisfaction which had been measured using the Anti-Clot Treatment Scale (ACTS) (a 15 point scale to score burden and benefit) or treatment satisfaction questionnaire for medication version II (TSQM VII which assess 4 subscales of convenience, effectiveness, global satisfaction and side effects based on Likert scales) \(^15,16\). Medication-related, review or intervention-related, and adverse outcomes. Overall, the outcomes were diverse with differing definitions, methods of data collection, varying time points, and different reporting methods.

**Patient Reported Satisfaction**

Greater satisfaction with DOACs was reported in five of the included studies using the ACTS tool. These studies showed a significant reduction in the burden score and a higher benefits score illustrating more satisfaction with DOAC treatment \(^26,27,29,38,43\). One study demonstrated a reduced ACTS burden score but stable or no change in the benefit score \(^30,39\). Only two studies showed increased satisfaction in the DOAC group based on the PACT Q2 tool \(^32,40\). Another study which used the PACT Q2 tool showed high satisfaction in both anticoagulation groups, VKA and DOAC \(^33\). One of the studies reported inconclusive results or dissatisfaction with DOAC therapy however these patients had been switched from warfarin and the questionnaire may correlate to the patients’ experiences of warfarin treatment \(^36\). Three of the studies which utilised the TSQM questionnaire reported greater patient satisfaction with DOAC treatment scores \(^27,28,30\). Okumura et al \(^43\) reported no difference in
satisfaction when utilising the TQSM score. Stephenson et al.\textsuperscript{35} used the Duke Anticoagulation treatment scale which confirmed patient satisfaction with DOAC treatment. Satisfaction with VKA versus DOAC was also analysed by Contreras Muruaga et al.\textsuperscript{42} however the patient population was the same as another study\textsuperscript{37} and therefore these results were excluded from this review to avoid duplication.

**Health Related Quality of Life (HRQoL)**

HRQoL was investigated by 6 different studies, which utilised either the Euro Qol 5 dimension of the Sawicki questionnaires. All 6 studies reported that HRQoL was similar among patients on VKA and DOACs\textsuperscript{25,31-33,41,42}. Contreras Muruaga et al.\textsuperscript{42} demonstrated that a higher QoL was associated with longer time in therapeutic range and better INR control. Four of the studies described a higher HRQoL score in the DOAC group but this was not statistically significant\textsuperscript{31-33,41}. Keita et al.\textsuperscript{33} showed that this higher QoL score can be attributed to the lack of blood monitoring associated with DOACs. Marques-Contreras et al.,\textsuperscript{41} highlighted that a significantly higher QoL score was confirmed in patients with established compliance after 12 months of treatment.

**Patient Reported Expectations, Compliance or Adherence**

Larochelle et al.\textsuperscript{40} used the perception of anticoagulation treatment questionnaire to determine patient expectation with anticoagulation treatment prior to initiation. The study found that there was no statistically significant difference between the groups however there was a greater expectation of adverse effects in the warfarin group.

Patient reported compliance was explored by Carrothers et al.\textsuperscript{44} using an investigator developed questionnaire and showed that the majority of patients prescribed rivaroxaban were complaint with treatment.

Patient reported medication adherence was investigated by 5 studies using the 8 point Morisky Medication Adherence Scale (MMAS-8)\textsuperscript{32-35}. Castellucci et al.\textsuperscript{47} used an abridged 4 point version of the MMAS tool. All 5 studies indicated that adherence was similar among patients treated with VKA and DOACs. Obamiro et al.\textsuperscript{34} highlighted that a higher adherence score was observed in the patient group which exhibited a higher knowledge of anticoagulation treatment.
Discussion

This systematic review provides the first overview of the use of PROS in anticoagulant treatment and has categorised an increasing body of evidence to establish the importance of PROs in patients treated with DOACs. The systematic search for this review yielded 21 articles (6 controlled studies and 15 observational studies) from 3231 screened articles. The studies focused on PROs such as patient-reported satisfaction, expectations, compliance and adherence as well as health-related quality of life. The majority of the studies described enhanced satisfaction in patients prescribed DOAC treatment using self-report scales. Studies highlighting patient reported expectations, adherence and compliance using the MMAS-8 tool showed that adherence was similar in both DOAC and warfarin groups however patients prescribed warfarin had more expectations of adverse events. It was identified that patients with greater knowledge of their anticoagulant treatment were more likely to adhere. HRQOL was investigated by some studies which demonstrated that there was no significant difference between the two groups. Increased HRQoL was observed in the DOAC group for a couple of studies however this was not statistically significant. In contrast a reduced HRQoL is observed in patients prescribed warfarin which correlates to poor INR control, a factor which does not influence DOAC treatment. 

Although DOACS are not associated with the same pharmacokinetics or pharmacodynamic issues as warfarin, they have presented with additional concerns surrounding medication adherence and therapeutic efficacy. Hence, PROs are a beneficial outcome measure in order to determine patient satisfaction, adherence and compliance with DOAC treatment. PROs offer a unique perspective of treatment effectiveness without the invasive blood testing and monitoring requirements associated with warfarin. These can often be more reliable that physiological parameters and informal interviews through the use of optimal validated tools as a method of categorising and measuring patient outcomes.

Warfarin and DOACs are equally as effective in the prevention or treatment of VTE and stroke. DOACs are associated with less bleeding risk and net benefit when compared to warfarin. However, the simple medication regime and lack of therapeutic monitoring associated with DOACS are likely to result in more patients and physicians opting and preferring DOAC treatment with proven satisfaction, adherence and likely HRQoL. Satisfaction has been
reported with warfarin treatment which comprises less complicated regimes and monitoring and management methods including self-monitoring, pharmacist inclusion or single point of testing at home \textsuperscript{52-54}.

Near patient testing and self-monitoring with warfarin have shown improved satisfaction rates than standard clinic monitoring with warfarin treatment. Studies have shown an improved quality of anticoagulation in patients who self-monitor and self-adjust their doses which results in an overall reduced incidence of VTE by around 50%, a 33% reduction in major haemorrhage and a reduction in mortality from all causes \textsuperscript{55}.

The World Health Organisation has reported that half of the patients prescribed regular medication for chronic illness do not adhere to their prescribed regimes \textsuperscript{56}. Factors which affect adherence are multiple and complicated in nature. Factors of non-adherence can be patient-related (lack of literacy, involvement or engagement), physician-related (prescribing of complex regimens or ineffective communication) or can be healthcare system related \textsuperscript{56}. Barriers to adherence and medication taking behaviour is complex and challenging to overcome therefore patient satisfaction to treatment plays a fundamental role in enhancing patient concordance, experience and overall preference for taking their medications for chronic conditions. Further evidence suggests that enhanced patient knowledge about anticoagulation treatment results in enhanced patient satisfaction therefore pharmacist are best placed experts in medicines to provide thorough counselling to patient through effective communication \textsuperscript{57-59}.

Therefore, healthcare professionals play an elemental role in educating and motivating patients to engage with their treatment plan to ensure maximum adherence with medication. Empowering and motivating patients as well as involving them in the decision making process is likely to provide profound benefit to the patient and overall healthcare economy due to reduced incidence of complications and costly hospitalisations. The European Heart Rhythm Association (EHRA) have issued a consensus statement which also highlights the importance of patient education an a vital element in the management of cardiac arrhythmias including AF. EHRA suggests that all patients should receive individualised and specially designed information which is specific to their needs, condition and treatment and repeated over time \textsuperscript{60}. A clear link has been established between greater treatment satisfaction resulting in enhanced adherence to treatment for chronic conditions \textsuperscript{61}. Patients reporting greater
satisfaction, improved quality of life and therefore higher adherence to DOACs they are more likely to concord with DOAC treatment resulting in successful treatment, fewer complication of stroke or VTE and reduced mortality. Incorporating shared-decision making processes into consultations is the optimal approach to achieve maximum patient satisfaction and improved QoL.

Warfarin, although an inexpensive drug, requires costly monitoring and is resource intensive which patients are known to dislike due to the regular clinic appointments and blood tests with up to 13 appointments a year and less than 65% of time spent in therapeutic range with a consequent increase in risk of stroke. DOAC on the other hand are costly drugs and this has been a nature of debate in order to achieve the most cost-effective anticoagulant treatment available on the NHS.

Cost effectiveness of DOACs is highly dependent and directly related on the costs of the alternative, VKA, with the associated adequate quality of monitoring and therapeutic control. However, this can be balanced with the enhanced patient preference of no monitoring with DOACs therefore indicating higher satisfaction, preference and overall QoL with DOACs.

Possible Weaknesses

This review comprised of a comprehensive literature search and extensive scrutiny of relevant articles for inclusion in order to minimise the risk of bias. However, meta-analysis and robust conclusions cannot be drawn because of significant heterogeneity in validated tool utilised, outcome measures, and publication bias. Overall, this review had several limitations that may affect its generalisability, including language bias (only English-language databases and journals were searched), selection bias (allocation concealment), and detection bias or performance bias (blinding related). Blinding of all study participants, personnel, and outcome assessors was not possible across all included studies because of the nature of the outcomes reported and study design (real world observational studies). Patients and professionals participating the in the studies were aware of the nature of the study carried out and intention behind completing the questionnaires chosen. Moreover, reporting bias cannot be ruled out. Finally, a limitation of PROs, is that they exclude patient with disability or low literacy skills and therefore may not be representative of the patient population or
present an accurate picture of patient acceptance of treatment therefore further work needs to be performed to ensure inclusion of these patient groups.

Conclusions

This review has established that the majority of patients are satisfied and would therefore prefer anticoagulation with DOACs when compared to warfarin for VTE and AF treatment and long term prevention of stroke. This has been identified by the increased satisfaction, adherence and HRQoL experienced by patients on DOACs which is likely to have substantial impact on the NHS burden, incidence of stroke complications and overall reduction in morbidity and mortality. However, heterogeneity in the analysed studies (randomised and observational studied) does not allow firm conclusions and statistical inference (meta-analysis). More original work should be carried out to strengthen this evidence.

Statement of originality

This work is submitted for publication in the British Journal of Clinical Pharmacology. The authors declare that this review has not been and, if accepted, will not be published in whole or in part in any other journal. All authors have read and approved the full manuscript in its submitted form.

Competing Interests

There are no competing interests to declare. All authors have read and approved the final draft. This review is part of a self-funded PhD project.
<table>
<thead>
<tr>
<th>Author - year of publication</th>
<th>Data collection period</th>
<th>Treatment/ Population</th>
<th>Study details</th>
<th>PRO Assessment</th>
<th>Sample size</th>
<th>Outcomes measured</th>
<th>Main findings of the study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients with Atrial Fibrillation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monz et al – 2013 25</td>
<td>December 2005 to December 2007</td>
<td><strong>Treatment:</strong> Dabigatran versus dose adjusted warfarin <strong>Population:</strong> for non-valvular AF <strong>Mean age:</strong> 71.5 years <strong>Female:</strong> 36.4%</td>
<td><strong>Design:</strong> RCT Subgroup of RE-LY population RE-LY = Prospective, randomised open-label, blinded end point evaluation <strong>Setting:</strong> 44 countries and 951 clinical centres</td>
<td>Patient reported health related quality of life using EQ-5D utility and visual analogue VAS scores, assessed at baseline, 3 and 12 months</td>
<td>1435 patients (497 in dabigatran 110mg BD, 485 dabigatran 150mg BD group and 453 warfarin group)</td>
<td>Changes in HRQoL over time 5 questions on 5 dimensions of health (mobility, self-care, usual; activities, pain/discomfort, anxiety/depression) and 3 levels of response</td>
<td><strong>HRQoL:</strong> No statistically significant difference between dabigatran groups or warfarin groups Utility weighted scores for Dabigatran 150mg BD ranged from 0.805 to 0.811 for dabigatran 110mg BD and did not change over the 1-year observation period. No difference between dabigatran and warfarin group except dabigatran 150mg at 3 months. None of the in-groups or between-group analyses were significant</td>
</tr>
<tr>
<td>Hohnloser et al – 2015 28</td>
<td>October 2012 - September 2013</td>
<td><strong>Treatment:</strong> Rivaroxaban vs standard therapy for cardioversion <strong>Population:</strong> Patients with AF requiring cardioversion</td>
<td><strong>Design:</strong> RCT Post hoc study of X-VERT trial, <strong>setting:</strong> conducted in 7 countries US, UK Canada, Netherlands,</td>
<td>Patient reported treatment satisfaction using User Treatment Satisfaction Questionnaire for medication Version II, completed after 705 patients completed the questionnaire</td>
<td>11 items, 4 subscales convenience, effectiveness, global satisfaction and side effects based on Likert scales</td>
<td></td>
<td><strong>Satisfaction:</strong> Rivaroxaban group reported increased score for convenience (81.74 vs 65.78), effectiveness (39.41 vs 32.95) and global satisfaction (82.07 vs 66.74), p&lt;0.0001.</td>
</tr>
<tr>
<td>Study</td>
<td>Time Period</td>
<td>Treatment</td>
<td>Population</td>
<td>Design</td>
<td>Setting</td>
<td>Patient reported treatment satisfaction</td>
<td>12 item burden scale (max 60 points) and 3 item benefits scale (max 15 points)</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>-----------</td>
<td>------------</td>
<td>--------</td>
<td>---------</td>
<td>----------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>Coleman et al – 2016</td>
<td>September 2015 to October 2016</td>
<td>Rivaroxaban for stroke prevention</td>
<td>Patients with non-valvular AF prescribed rivaroxaban</td>
<td>non-randomised controlled trial</td>
<td>308 investigational sites in 21 countries</td>
<td>Patient reported treatment satisfaction using ACTS implemented at baseline and 3 months after switch</td>
<td>1291 patients with prior warfarin treatment switched to rivaroxaban</td>
</tr>
<tr>
<td>Koretsune et al – 2017</td>
<td>31st February to 30th June 2012</td>
<td>Apixaban</td>
<td>Patients switched from warfarin to apixaban</td>
<td>RCT</td>
<td>149 institutions in Japan</td>
<td>Patient reported treatment satisfaction using ACTS, implemented before switch and after 12 weeks of treatment with apixaban</td>
<td>697 patients switched to apixaban</td>
</tr>
<tr>
<td>Alegret et al – 2014</td>
<td>June 2012</td>
<td>VKA or NOAC</td>
<td>Patients with AF undergoing</td>
<td>Prospective study</td>
<td></td>
<td>Patient reported HRQoL in patients on oral anticoagulants using Sawicki Questionnaire,</td>
<td>416 patients. 351 in VKA group and 65 in DOAC (59 on dabigatran and 5 in</td>
</tr>
<tr>
<td>Study</td>
<td>Date Range</td>
<td>Treatment</td>
<td>Population</td>
<td>Mean Age</td>
<td>Female</td>
<td>Design</td>
<td>Setting</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------</td>
<td>-----------</td>
<td>-------------------------------------</td>
<td>----------</td>
<td>--------</td>
<td>----------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Hanon et al – 2016 38</td>
<td>April 2013 to June 2014</td>
<td>Treatment: patients previously treated with warfarin and switched to rivaroxaban</td>
<td>Population: Non valvular AF patients</td>
<td>Mean age: 74.8 years Female: 37%</td>
<td></td>
<td></td>
<td>Setting: conducted in 67 hospitals in Spain</td>
</tr>
<tr>
<td>Marquez-Contreras et al 2016 41</td>
<td>May 2013 to April 2015</td>
<td>Treatment: patients on rivaroxaban</td>
<td>Population: Patients with non valvular atrial fibrillation</td>
<td>Mean age – 75 years Female: 50.3%</td>
<td></td>
<td></td>
<td>Setting: conducted in 160 primary and specialty care centres in Spain</td>
</tr>
<tr>
<td>Study</td>
<td>Date</td>
<td>Treatment</td>
<td>Design</td>
<td>Population</td>
<td>Setting</td>
<td>Patient reported</td>
<td>EuroQol 5D</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-----------</td>
<td>--------</td>
<td>------------</td>
<td>---------</td>
<td>-----------------</td>
<td>----------</td>
</tr>
<tr>
<td>Keita et al – 2017</td>
<td>July 2014 to July 2015</td>
<td>Treatment: patients prescribed warfarin or switched to DOAC or initiated on DOAC treatment</td>
<td>Observational descriptive study, Setting: conducted in multicentre in France</td>
<td>VTE patients</td>
<td>Mean age: 60.4 years, Female: 46%</td>
<td>Patient reported adherence, satisfaction and quality of life using Morisky Medication Adherence Scale, MMAS-8, EQ-5D, perception of anticoagulation questionnaire part 2, administered after 3 months treatment and 6 months treatment</td>
<td>100 patients 50 in warfarin group and 50 in DOAC group</td>
</tr>
<tr>
<td>Contreras Muruaga et al 2017</td>
<td>September 2014 to March 2015</td>
<td>Treatment: patients with non-valvular atrial fibrillation</td>
<td>Observational cross-sectional study, Setting: 63 neurology departments in Spain</td>
<td>Patients with non-valvular atrial fibrillation</td>
<td>Mean age: 75 years, Female: 44.2%</td>
<td>Patient reported satisfaction, QoL and perceptions of VKA versus DOACs (only QoL included)</td>
<td>1337 patients 587 patients DOAC 750 patients VKA</td>
</tr>
<tr>
<td>Stephenson et al 2018</td>
<td>October 2011 to June 2014</td>
<td>Treatment: patients prescribed warfarin</td>
<td>Hybrid US observational study</td>
<td>Patients prescribed warfarin,</td>
<td>Patient reported adherence using Morisky Medication</td>
<td>675 patients 271 in warfarin group</td>
<td>Validated patient reported tool. Measures medication taking</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Treatment</td>
<td>Population</td>
<td>Setting</td>
<td>Adherence Scale</td>
<td>Design</td>
<td>Adherence behaviours and circumstance influencing adherence.</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-----------</td>
<td>------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>de Caterina et al – 2018</td>
<td>2012 to 2013</td>
<td>Treatment: on stable VKA or switched to NOAC (rivaroxaban, dabigatran or apixaban)</td>
<td>Population: Patients with non-valvular AF</td>
<td>Setting: conducted in 14 institutions in the US</td>
<td>Adherence Scale MMAS-8 duke anticoagulation treatment scale, administered at baseline, and at 4, 8 and 12 months</td>
<td>Design: prospective study PREFER in AF Registry Sub study Setting: conducted in 7 European countries</td>
<td>Patient reported quality of life and satisfaction using PACT- Q2 and EQ-SD-5L questionnaires, administered at baseline and at 1 year follow up</td>
</tr>
<tr>
<td>Koretsune et al – 2018</td>
<td>April 2012</td>
<td>Treatment: Rivaroxaban in patients previously on warfarin</td>
<td>Population: non-valvular AF patients</td>
<td>Setting: conducted at 124 sites in Japan</td>
<td>Patient reported treatment satisfaction ACTS and Treatment satisfaction questionnaire for Medication Ver II, administered at</td>
<td>Design: post marketing surveillance study of a prospective study Setting: conducted at 124 sites in Japan</td>
<td>665 patients included in the study</td>
</tr>
<tr>
<td>Study</td>
<td>Time Period</td>
<td>Treatment</td>
<td>Population</td>
<td>Design</td>
<td>Setting</td>
<td>Patients</td>
<td>Expectations</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>-----------</td>
<td>------------</td>
<td>--------</td>
<td>---------</td>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Larochelle et al – 2018&lt;sup&gt;40&lt;/sup&gt;</td>
<td>February 2013 to December 2014</td>
<td>Patients newly prescribed an oral anticoagulant (either warfarin or DOAC, apixaban, rivaroxaban or dabigatran)</td>
<td>Patient with non valvular atrial fibrillation</td>
<td>Prospective observational study</td>
<td>conducted in hospitals in Canada</td>
<td>159 patients included (71 on warfarin and 88 on DOAC mainly rivaroxaban)</td>
<td>Patients expectations and satisfaction with oral anticoagulation treatment using PACT Q1 and PACT Q2 questionnaires, administered before treatment and at 3 and 6 months post discharge</td>
</tr>
<tr>
<td>Benzimra et al – 2018&lt;sup&gt;32&lt;/sup&gt;</td>
<td>June 2013 to November 2015</td>
<td>Patients receiving oral anticoagulants VKA/ DOAC (dabigatran, rivaroxaban or apixaban), or switched treatments</td>
<td>patient with atrial fibrillation</td>
<td>Real life observational descriptive cross-sectional study</td>
<td>conducted in various recruitment sites in France</td>
<td>200 patients (89 on VKA, 52 on DOAC, 50 switched to DOAC, 9 switched to VKA)</td>
<td>Quality of life, treatment satisfaction and adherence using 3 validated questionnaires- Euro-QoL 5 dimensions 3 levels visual analog scale EQ-5D, Perception of Anticoagulation Treatment Questionnaire</td>
</tr>
<tr>
<td>Study</td>
<td>Time Period</td>
<td>Treatment</td>
<td>Population</td>
<td>Design</td>
<td>Setting</td>
<td>Patient Satisfaction with Anticoagulant Treatment</td>
<td>Adherence</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>-----------</td>
<td>------------</td>
<td>--------</td>
<td>---------</td>
<td>--------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Okumura et al 2018</td>
<td>Sept 2013 and December 2015</td>
<td>patients on anticoagulation (VKA/ DOAC)</td>
<td>Patients with non valvular atrial fibrillation</td>
<td>Sub study of SAKURA AF registry</td>
<td>conducted in 40 institutions in Japan</td>
<td>ACTS – 17 item questionnaire to measure patient satisfaction addressing burden and benefits. The TSQM II covers 4 domains, effectiveness, side effects, convenience and global satisfaction.</td>
<td>There were no significant differences in the TSQM II questionnaire between the 2 groups. The ACTS burden scores were significantly higher for the DOAC group than the warfarin group showing greater satisfaction with treatment.</td>
</tr>
<tr>
<td>Fernandez et al 2018</td>
<td>ALADIN Study: September 2014 to March 2015 ESPARTA Study: October 2015 to March 2016</td>
<td>patients prescribed VKA or DOAC</td>
<td>Patients with non-valvular AF</td>
<td>2 different cross-sectional studies combined (ALADIN and ESPARTA studies),</td>
<td>conducted at various departments in Spain</td>
<td>ALADIN study: 472 patients ESPARTA study: 837 patients. 1309 patients in total, 902 VKA group ad 407 DOAC group</td>
<td>ACTS is patient reported measure of satisfaction with anticoagulation. 12 items that assess perceived burdens, 4 items to assess perceived benefits,</td>
</tr>
</tbody>
</table>
### Treatment: Prescribed Oral Anticoagulants

**Population:** Patients with atrial fibrillation

**Age Range:** 18-65 years

**Female:** 68%

**Design:** Secondary analysis of the Australian oral anticoagulation survey

**Setting:** Conducted through online recruitment in Australia

**Predictors of adherence and patient related factors of adherence using Morisky Medication Adherence Scale (MMAS-8), anticoagulation knowledge tool and PACT Q1 and Q2 questionnaires**

**386 patients**
- Warfarin: 100 patients
- Apixaban: 121 patients
- Rivaroxaban: 123 patients
- Dabigatran: 42 patients

**MMAS-8 to assess levels of adherence. AKT to assess OAC knowledge & Perception of anticoagulation treatment questionnaires assessing treatment expectation, global convenience and satisfaction.**

**Adherence:** No significant difference in adherence seen between patients taking warfarin and DOACs. Patients in the high adherence group showed a higher anticoagulation knowledge.

**Satisfaction:** Satisfaction scores were greater in the medium adherence groups.

### Patients with VTE (PE and DVT)

**Bamber et al, 2013**

- **March 2007 to Sept 2009**
- **Treatment:** Rivaroxaban vs enoxaparin/warfarin for DVT
- **Population:** Patients with DVT
- **Mean age:** 56.8 years
- **Female:** 42.4%
- **Design:** RCT Sub-study analysis of EINSTEIN DVT study
- **Setting:** Conducted in 7 countries (US, UK, Canada, Netherlands, France, Germany and Italy)
- **Patient reported treatment satisfaction using ACTS score, assessed at 12 months of treatment**
- **1472 patients**
- **ACTS 15-point score Burden and Benefits**
- **Satisfaction:** Clinically significant reduction in ACTS burden (55.2 vs 52.6, p<0.0001) and improvement in ACTS benefit (11.7 vs 11.5, p=0.006) in rivaroxaban group (compared with warfarin)

**Prins et al, 2014**

- **March 2007 to March 2011**
- **Treatment:** Rivaroxaban vs standard therapy (enoxaparin/warfarin)
- **Design:** Sub analysis of EINSEIN PE study, setting: conducted in 7 countries
- **Patient reported treatment satisfaction using ACTS and Treatment satisfaction**
- **2397 patients**
- **ACTS 15 point scale Burden Scale and Benefit scale**
- **Satisfaction:** Rivaroxaban group reported statistically significant increase in ACTS benefit (11.9 vs 11.4, p<0.0001) and less ACTS burden (55.4 vs 51.9, p<0.0001)
<table>
<thead>
<tr>
<th>Study</th>
<th>Period</th>
<th>Study Details</th>
<th>Population</th>
<th>Design</th>
<th>Setting</th>
<th>Treatment</th>
<th>Mean Age</th>
<th>Female</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrothers et al – 2014</td>
<td>May 2010 to December 2011</td>
<td>Treatment: Patients prescribed rivaroxaban</td>
<td>US, UK Canada, Netherlands, France, Germany and Italy</td>
<td>Prospective study</td>
<td>Self-administered questionnaire, conducted in single orthopaedic centre in Canada</td>
<td>Mean age: 58 years Female: 44%</td>
<td>Yes / no Questionnaire developed by the investigators to measure adherence/compliance</td>
<td>Statistically significant improved TSQM II scores in the rivaroxaban group p&lt;0.0001 for all 4 factors, effectiveness, side-effects, convenience and global satisfaction</td>
<td></td>
</tr>
</tbody>
</table>

| Castellucci et al - 2015 | September 2012 - September 2013 | Treatment: Patients on oral anticoagulants (VKA, rivaroxaban, dabigatran and apixaban) | US, UK Canada, Netherlands, France, Germany and Italy | Cross-sectional survey | Self-reported anticoagulant adherence using the 4 item Morisky scale, administered once | Mean age: 66 years Female: 61% | 500 patients (367 on VKA, 130 on DOACS) | Adherence: Self-reported adherence using the 4 item Morisky scale was 56.2% on VKA and 57.1% on DOAC. Adherence was similar in both groups. |
Table 2: Risk of Bias Assessment (Cochrane RCTs) for Controlled Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation</th>
<th>Allocation Concealment</th>
<th>Binding-participants and personnel</th>
<th>Binding-outcome assessment</th>
<th>Incomplete outcome data</th>
<th>Selective outcome reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bamber et al 2013</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Coleman et al 2016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hohnloser et al 2015</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Koretsune et al 2017</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Monz et al 2013</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Prins et al 2015</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

+ = low risk of bias  
- = high risk of bias  
? = unclear risk of bias
Table 3: Newcastle-Ottawa Quality Assessment Scale and analysis of observational studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample Representativeness</th>
<th>Sample size</th>
<th>Non-respondents</th>
<th>Ascertainment of exposure</th>
<th>Comparability</th>
<th>Assessment of outcome</th>
<th>Statistical test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alegret et al 2014</td>
<td>selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Benzimra et al 2018</td>
<td>selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Carrothers et al 2014</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>-</td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td>Castellucci et al 2015</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>De Caterina et al 2018</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td>Fernandez et al 2018</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td>Hanon et al 2016</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td>Keita et al 2017</td>
<td>selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Koretsune et al 2018</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td>Larochelle et al 2018</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Marquez-Contreras et al 2017</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td>Muruaga et al 2017</td>
<td>selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Obamiro et al 2018</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Okumura et al 2018</td>
<td>Selected</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Stephenson et al 2018</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>**</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

7-8 * = good studies  
5-6 * = satisfactory studies  
0-4 * = unsatisfactory studies
References


20. Tan X, Patel I, Chang J. Review of the four item Morisky medication adherence scale (MMAS-4) and eight item Morisky medication adherence scale (MMAS-8). *Innovations In Pharmacy* 2014;5(3):5.


36. De Caterina R, Bruggenjurgen B, Darius H, et al. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-


